Deadline: 17 January 24

The Research Foundation on Juvenile Diabetes (JDRF) is offering funding to accelerate the identification and validation of reagents that promote immune rebalancing and protection of beta cell function by modulating immune cell traffic to pancreatic islets.

SEARCH. CHOOSE. APPLYDiscover Premium NGO Funding GrantsThousands of opportunities at your fingertips for just US$ 29/year Hurry! Discount offer ends soon.JOIN TODAY

JDRF, the world's leading not-for-profit organisation with a mission to improve the lives of people with DM1 by accelerating advances for DM1, aims to catalyse and support innovative studies that will improve the lives of people with DM1. health and beta cell function. One potential therapeutic strategy to stop the immune-mediated destruction of beta cells is to limit immune traffic to the islets, however this approach has not been extensively evaluated in human-relevant models. The identification and validation of new strategies to target islet localisation pathways while avoiding widespread immunosuppression is of great interest for this funding opportunity.

Information on financing

• This programme will grant grants of up to US$ 900,000 over 3 years. The level of funding will vary depending on the overall scope and objectives of the proposal. JDRF may consider applications with a larger scope (time and/or budget) when there is a strong justification.
• In response to this announcement, LOIs can be submitted to the following mechanisms JDRF Strategic Research Agreement (SRA) or Discovery and Development Programme grant Industry (IDDP) :
  • Strategic Research Agreements
    • The SRA application can include up to 10% of indirect costs as part of the US$ 900 thousand.
  • Industry Development and Discovery Programme
    • For IDDP applications, candidates must contact the JDRF scientific contact before submitting an LOI.
    • IDDP applications do not allow indirect costs.

Project Eligibility

• Examples of proposals that would be considered in this call include, but are not limited to:
  • Development or validation of reagents that target receptors (e.g. chemokine receptors, sphingolipid receptors, etc.) or adhesion molecules involved in the trafficking of pro-inflammatory and/or autoreactive immune cells to the pancreas. Approaches that have been previously tested in T1D should be incrementally evaluated in the next phase of development.
  • Realignment of mechanisms and clinical-grade reagents involved in cell trafficking validated in other diseases for evaluation in DM1.
• Priority will be given to approaches that:
  • Proposing methods to combat cell trafficking, avoiding generalised immunosuppression. Validation of T1D reagents that have been clinically evaluated in other disease indications.
  • Projects that include research protocols using human samples or model systems relevant to humans.
• Outside the scope of this request:
  • The studies have focused exclusively on broad phenotyping of knockout or transgenic models that do not directly measure the outcome or onset of DM1.
  • The studies focused exclusively on the broad characterisation of trafficking targets based on large data sets.
  • Projects that seek to test reagents targeting pathways not involved in the migration of immune cells.

Election criteria

• They accept Letters of Intent (LOI) from researchers, established teams, organisations and industry with demonstrated and appropriate experience for the tasks.
• Examples of proven knowledge desired: immunology, molecular biology, bioinformatics, human beta cell biology, targeting the generation of reagents (antibodies, oligonucleotides, nanomedicines, small molecule inhibitors, etc.), knowledge with animal models to assess migratory inhibition with an emphasis on drug metabolism and pharmacokinetics.
• Applications may be submitted by domestic and foreign non-profit organisations, public and private entities such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government. Applicants must hold an MD, DMD, DVM, Ph.D. or equivalent and have a teaching position or equivalent at a college, university, school medical school or other research centre.
• There are no citizenship requirements for this programme. To ensure continued excellence and diversity among applicants and awardees, the JDRF welcomes applications from all qualified individuals and encourages applications from people with disabilities, women and members of minority groups under-represented in the sciences.

For more information, visit JDRF .